NASDAQ:IBB - iShares Nasdaq Biotechnology ETF Stock Price, Forecast & News

iShares Nasdaq Biotechnology ETF trades on the NASDAQ under the ticker symbol "IBB."

iShares Nasdaq Biotechnology ETF announced a quarterly dividend on Monday, December 16th. Investors of record on Tuesday, December 17th will be given a dividend of $0.0578 per share on Friday, December 20th. This represents a $0.23 annualized dividend and a yield of 0.19%. The ex-dividend date is Monday, December 16th. View iShares Nasdaq Biotechnology ETF's Dividend History.

iShares Nasdaq Biotechnology ETF shares split on the morning of Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly created shares were issued to shareholders after the closing bell on Thursday, November 30th 2017. An investor that had 100 shares of iShares Nasdaq Biotechnology ETF stock prior to the split would have 300 shares after the split.

Media headlines about IBB stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. iShares Nasdaq Biotechnology ETF earned a media sentiment score of -4.2 on InfoTrie's scale. They also gave press coverage about the financial services provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for iShares Nasdaq Biotechnology ETF.

Some companies that are related to iShares Nasdaq Biotechnology ETF include DNP Select Income Fund (DNP), Nuveen Municipal Value Fund (NUV), Adams Diversified Equity Fund (ADX), PIMCO Corporate&Income Opportunity Fund (PTY), Hercules Capital (HTGC), Gabelli Equity Trust (GAB), Tri-Continental (TY), Royce Value Trust (RVT), Liberty All-Star Equity Fund (USA), Boulder Growth & Income Fund (BIF), Apollo Investment (AINV), AllianceBernstein Global Hgh Incm Fd (AWF), General American Investors (GAM), PIMCO High Income Fund (PHK) and Blackrock Muniyield Insured Fund (MYI).

Based on aggregate information from My MarketBeat watchlists, some companies that other iShares Nasdaq Biotechnology ETF investors own include NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Walt Disney (DIS), Bank of America (BAC), Tesla (TSLA), Cisco Systems (CSCO), Gilead Sciences (GILD), Micron Technology (MU) and Alphabet (GOOG).

iShares Nasdaq Biotechnology ETF's stock is owned by many different of institutional and retail investors. Top institutional shareholders include PNC Financial Services Group Inc. (0.91%), Public Sector Pension Investment Board (0.51%), Crestwood Advisors Group LLC (0.36%), Janney Capital Management LLC (0.31%), First Republic Investment Management Inc. (0.33%) and Great West Life Assurance Co. Can (0.28%).

IBB stock was sold by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Main Management LLC, Tower Research Capital LLC TRC, Williams Jones Wealth Management LLC., Private Advisor Group LLC, Moors & Cabot Inc., Crestwood Advisors Group LLC and Ladenburg Thalmann Financial Services Inc..

IBB stock was purchased by a variety of institutional investors in the last quarter, including Public Sector Pension Investment Board, Janney Capital Management LLC, Estate Counselors LLC, Madison Asset Management LLC, CHURCHILL MANAGEMENT Corp, Cavalier Investments LLC, Amia Capital LLP and Madison Wealth Management.

Shares of IBB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IBB stock can currently be purchased for approximately $122.89.

iShares Nasdaq Biotechnology ETF has a market capitalization of $7.59 billion. View Additional Information About iShares Nasdaq Biotechnology ETF.